Mobile Site ›
Print Friendly View

Test ID: TIAG    
Tiagabine Concentration, Serum

Secondary ID A test code used for billing and in test definitions created prior to November 2011

82524

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

This test is used for monitoring tiagabine therapy. Because tiagabine has a wide therapeutic index and dose-dependent toxicity, routine drug monitoring is not indicated in all patients. Drug monitoring is indicated when initiating concomitant therapy with antiepileptic drug that induce hepatic enzymes and when the patient does not respond to treatment to ascertain whether treatment failure is due to noncompliance or nonresponse to the drug.

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

Tiagabine (Gabitril) is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. It is frequently administered to patients receiving at least 1 concomitant antiepileptic drug (AED).(1) Tiagabine is a selective blocker of gamma-aminobutyric acid (GABA) uptake into presynaptic neurons. Tiagabine binds to recognition sites associated with the GABA uptake carrier. By this action, tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surface of post-synaptic cells.(1,2)

 

Tiagabine has an elimination half-life of 7 to 9 hours in normal volunteers. In patients receiving enzyme-inducing AEDs, the elimination half-life decreases to 4 to 7 hours. Phenytoin, phenobarbital, and carbamazepine are AED enzyme inducers; valproate and gabapentin are not. Tiagabine is not considered to be an enzyme-inducing AED.(2,6)

 

Tiagabine reaches peak serum concentration approximately 45 minutes following an oral dose in the fasting state. Tiagabine is well absorbed with food slowing the absorption rate but not altering the extent of absorption (high fat diet prolongs peak serum concentrations to about 2.5 hours). Tiagabine is >95% absorbed, with oral bioavailability of about 90%. Tiagabine pharmacokinetics are linear over the typical dose range of 2 to 24 mg. Steady-state is achieved within 2 days. Tiagabine is 96% bound to human plasma proteins, mainly to serum albumin and alpha-1-acid glycoprotein. Coadministration with valproate reduces protein binding to 94%, increasing the free fraction of tiagabine by 40%.(3,6)

 

Based on in vitro data, tiagabine is likely to be metabolized by the 3A isoform subfamily of hepatic cytochrome P450 (CYP 3A), although contributions to the metabolism from CYP 1A2, CYP 2D06, or CYP 2C19 have not been excluded.(3)

Method Name A short description of the method used to perform the test

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Tiagabine, S

Aliases Lists additional common names for a test, as an aid in searching

Gabitril (Tiagabine)
Tiagabine (Gabitril)